Pharmaceutical company Pharmaxis (ASX:PXS, Nasdaq:PXSL) is pleased to announce that
additional results of its recently completed international Phase III trial of Bronchitol in patients
with cystic fibrosis have been presented at the 2009 European Cystic Fibrosis Conference in
Brest, France.

Full release - 16.06.2009 - Phase 3 Cystic Fibrosis Trial Results Presented at European Conference (35KB)